Bevacizumab plus xelox as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer

被引：0
|
作者：
Gruenberger, Thomas
Tamandl, Dietmar
Herbst, Friedrich
Scheithauer, Werner
Zielinski, Christoph
Gruenberger, Birgit
机构：
[1] Med Univ Vienna, Dept Gen Surg, Hepatobiliary Serv, Vienna, Austria
[2] Med Univ Vienna, Dept Oncol, Vienna, Austria
来源：
ANNALS OF ONCOLOGY | 2006年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：128 / 128
页数：1
相关论文
共 50 条
  • [21] A prospective study of XELOX plus bevacizumab as first-line therapy in Japanese patients with metastatic colorectal cancer (KSCC0902)
    Takeuchi, Masaaki
    Ogata, Yutaka
    Tanaka, Takaho
    Kaibara, Atsushi
    Emi, Yasunori
    Saeki, Hiroshi
    Oki, Eiji
    Sadanaga, Noriaki
    Kusumoto, Tetsuya
    Touyama, Tetsuo
    Matsushita, Hiroo
    Shimokawa, Mototugu
    Baba, Hideo
    Shirouzu, Kazuo
    Maehara, Yoshihiko
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [22] Phase I/II Study of Capecitabine Plus Oxaliplatin (XELOX) Plus Bevacizumab As First-line Therapy in Japanese Patients with Metastatic Colorectal Cancer
    Doi, Toshihiko
    Boku, Narikazu
    Kato, Ken
    Komatsu, Yoshito
    Yamaguchi, Kensei
    Muro, Kei
    Hamamoto, Yasuo
    Sato, Atsushi
    Koizumi, Wasaburo
    Mizunuma, Nobuyuki
    Takiuchi, Hiroya
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2010, 40 (10) : 913 - 920
  • [23] Cost-effectiveness analysis of XELOX versus XELOX plus bevacizumab for metastatic colorectal cancer in a public hospital school
    Andrea Queiróz Ungari
    Leonardo Régis Leira Pereira
    Altacílio Aparecido Nunes
    Fernanda Maris Peria
    BMC Cancer, 17
  • [24] EFFECTIVENESS OF CHEMOTHERAPY WITH OXALIPLATIN, CAPECITABINE AND BEVACIZUMAB (XELOX plus BEV) IN SECOND LINE THERAPY OF METASTATIC COLORECTAL CANCER (MCRC)
    Arzykulov, Z.
    Chichua, N.
    Smagulova, K.
    Khamidullina, G.
    Mukanova, S.
    Suriya, K.
    ANNALS OF ONCOLOGY, 2010, 21 : 32 - 32
  • [25] Bevacizumab plus XELOX as first-line treatment of metastatic colorectal cancer:The OBELIX study
    Lorenzo Antonuzzo
    Elisa Giommoni
    Davide Pastorelli
    Tiziana Latiano
    Ida Pavese
    Domenico Azzarello
    Michele Aieta
    Ilaria Pastina
    Francesca Di Fabio
    Alessandro Bertolini
    Domenico Cristiano Corsi
    Selene Mogavero
    Valentina Angelini
    Mario Pazzagli
    Francesco Di Costanzo
    World Journal of Gastroenterology, 2015, (23) : 7281 - 7288
  • [26] Cost-effectiveness analysis of XELOX versus XELOX plus bevacizumab for metastatic colorectal cancer in a public hospital school
    Ungari, Andrea Queiroz
    Leira Pereira, Leonardo Regis
    Nunes, Altacilio Aparecido
    Peria, Fernanda Maris
    BMC CANCER, 2017, 17
  • [27] Bevacizumab plus XELOX as first-line treatment of metastatic colorectal cancer: The OBELIX study
    Antonuzzo, Lorenzo
    Giommoni, Elisa
    Pastorelli, Davide
    Latiano, Tiziana
    Pavese, Ida
    Azzarello, Domenico
    Aieta, Michele
    Pastina, Ilaria
    Di Fabio, Francesca
    Bertolini, Alessandro
    Corsi, Domenico Cristiano
    Mogavero, Selene
    Angelini, Valentina
    Pazzagli, Mario
    Di Costanzo, Francesco
    WORLD JOURNAL OF GASTROENTEROLOGY, 2015, 21 (23) : 7281 - 7288
  • [28] Preliminary Efficacy and Safety of Camrelizumab in Combination With XELOX Plus Bevacizumab or Regorafenib in Patients With Metastatic Colorectal Cancer: A Retrospective Study
    Zhou, Hong
    Wang, Yuehui
    Lin, Yanfang
    Cai, Wenjie
    Li, Xiaofeng
    He, Xiaomeng
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [29] Modified FOLFOX6 and Bevacizumab As Neoadjuvant Chemotherapy for Patients With Potentially Curable Bilobar Liver Metastases From Colorectal Cancer
    Maeda, Atsuyuki
    Isogai, Masatoshi
    Kaneoka, Yuji
    GASTROENTEROLOGY, 2013, 144 (05) : S1079 - S1079
  • [30] XELOX (capecitabine plus oxaliplatin):: Active first-line therapy for patients with metastatic colorectal cancer
    Cassidy, J
    Tabernero, J
    Twelves, C
    Brunet, R
    Butts, C
    Conroy, T
    Debraud, F
    Figer, A
    Grossmann, J
    Sawada, N
    Schöffski, P
    Sobrero, A
    Van Cutsem, E
    Diaz-Rubio, E
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (11) : 2084 - 2091
12345